InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (98)	5/25/2001 7:18:56 PM
From: rkrw	Read Replies (1) of 508

IJ, Thanks for the heads up on the presentation. 180 patients enrolled as of 5/18 is a nice step up in the ramp rate. For reference, they were at 111 on April 5. I was starting to get concerned that off label availability could significantly delay trial enrollment, so I'm extremely pleased to see the momentum in recent enrollment. Harkonen is also much more firm in his guidance for complete enrollment by 6/30 than previously. He was hedging last time I heard them present. So a good sign that the end is nearing. They plan to take an interim look in early '02 to make sure their trial is sufficiently powered, however no look at efficacy. Expect formal completion of the trial in August '02, with results by year end '02. He also noted they expect $8.4M in sales for Q4.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next